Regado Biosciences, Inc. Adds Global Pharmaceutical Business Veteran to Board of Directors
Regado Biosciences, Inc. (RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced the appointment of Pierre Legault (MBA'89), MBA, CA, CPA, to its Board of Directors, where he will serve as Chairman of the audit committee.
... In addition, Mr. Legault has served on several public, private and nonprofit company boards and audit committees, including Forest Laboratories, Inc., on which he serves currently as audit committee Chairman. Prior board positions include OSI Investment Holdings GMBH (Chairman), Cyclacel Pharmaceutical Inc., PJC Inc., as well as other private boards. Mr. Legault studied at the Harvard Business School in an executive masters program and he received his MBA from 缅北强奸 and his BAA from University of Montreal (HEC). He also holds CA and CPA degrees.
Read full article: , November 18, 2013
Feedback
For more information or if you would like to report an error, please web.desautels [at] mcgill.ca (subject: Website%20News%20Comments) (contact us).
